This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. General practitioners (GPs) participating in the study will have access to the website, which provides evidence-based algorithms for the management of common mental health conditions, including anxiety and sleep disorders. Prescription data and patient characteristics will be extracted from the French national health insurance database (DCIR). The primary outcome is the proportion of new benzodiazepine users whose prescriptions comply with recommended duration guidelines. Multilevel logistic regression models will assess the intervention effect, adjusting for patient- and GP-level factors.
Being a general practitioner or a specialist in general medicine.
Practicing in the Occitanie region.
Working in private practice.
Being registered under Sector 1 fee agreements.
None
Parallel
Training
Other interventionTraining intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.
Compliance with recommended maximum duration of benzodiazepine prescriptions among new users
Primary outcome measure: adherence to recommended prescription duration (yes/no) for benzodiazepines A patient is considered to have a prescription duration for benzodiazepines that is either adherent or non-adherent if they had no benzodiazepine exposure in the previous year and their duration of exposure during the first treatment episode: 1. is less than 12 weeks for anxiolytic benzodiazepines, 2. is less than 28 days for hypnotic benzodiazepines and related drugs, in accordance with current recommendations.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
